

CANCER EXPERTISE FROM FINLAND

BUSINESS
FINLAND

#FINLANDWORKS



TABLE OF CONTENTS

BUSINESS
FINLAND

- WHY FINLAND
- FINNISH EXPERTISE ALONG THE CANCER CARE PATH
- SUPPORTING ECOSYSTEMS AND PLATFORMS
- PHARMACEUTICALS, BIOTECH AND RESEARCH
- DIAGNOSTICS, TESTING AND SCREENING
- DIGITAL CANCER SOLUTIONS
- TREATMENT, QUALITY AND CANCER CARE
- LIFE MANAGEMENT
- CONTACT INFORMATION

In Finland we create, combine, and enhance technologies, data and practices exponentially to improve the health of our citizens and people a round the world.

WHY FINLAND?

BUSINESS
FINLAND

The Finnish health sector is built on world-class research and technology know-how and has one of the most efficient healthcare systems in the world-offering high value for money spent.

High-level cancer innovations and advanced digital skills are recognized by leading global cancer and oncology companies (e.g. Varian Noona, Elekta-Kaiku Health)

The Finnish healthcare system has spurred the growth of cutting-edge research and treatment in specialist areas such as: cancer, neurodegenerative diseases and disorders, orthopedics, and genetics research. Based on the average number of citations per clinical cancer publication, Finland is the number one country in cancer research. Each Finnish cancer article receives an average of 26.4 citations.

Globally, Helsinki University Hospital (HUS) is recognized as a world leader in cancer research and care. As the first hospital in northern Europe awarded the Comprehensive Cancer Centre (CCC) accreditation by the Organization of European Cancer Institutes (OECI), HUS has developed into a nexus of cutting-edge medical research and treatment.

Our ambition is to be a model country of sustainable personalized healthcare.

WHY FINLAND?

BUSINESS
FINLAND

#1

IN FINLAND, THE 5-YEAR SURVIVAL RATE OF MOST CANCERS IS AMONG THE HIGHEST IN THE WORLD

CONCORD-3: GLOBAL SURVEILLANCE OF TRENDS IN CANCER SURVIVAL 2000–14

#1

AVAILABILITY OF THE LATEST MEDICAL TECHNOLOGIES

WORLD ECONOMIC FORUM GLOBAL COMPETITIVENESS REPORT 2017–18

#1

HEALTH TECH IS THE LARGEST AND ONE OF THE FASTEST-GROWING EXPORT SEGMENTS OF THE FINNISH HIGH-TECH INDUSTRY

HEALTHTECH FINLAND 2019

#1

AVAILABILITY OF SCIENTISTS AND ENGINEERS

WORLD ECONOMIC FORUM GLOBAL COMPETITIVENESS REPORT 2017–18

FINNISH EXPERTISE ALONG THE CANCER CARE PATH

BUSINESS
FINLAND

1. ECOSYSTEMS AND PLATFORMS

Cancer IO, Euro-BioImaging, FICAN Mid, FICAN South, Fingenious, FIMM, iCAN, InFlames, KCT

4. DIGITAL CANCER SOLUTION

Adesante, Aiforia, BC Platforms, Buddy Healthcare, Grundium, Innomentarium, Kaiku Health, MediSapiens, Planmed, Varian Medical, VEIL.AI

2. PHARMACEUTICALS, BIOTECH AND RESEARCH

Abomics, Aurlide, Biovian, Brinter, Euformatics, Faron Pharmaceuticals, FinVector, Genevia Technologies, Orion, Pharmatest, Tenboron, TILT Biotherapeutics, Valo Therapeutics

5. TREATMENT, QUALITY AND CANCER CARE

BCB Medical, Clinic Helena, Docrates Cancer Center, Injeq, Modulight, MVision AI, Orton

3. DIAGNOSTICS, TESTING AND SCREENING

Biopsense, Blueprint Genetics, Finnadvance, LS CancerDiag, MEGIN, Misvik Biology, Mylab, Oflectomics, Optomed

6. LIFE MANAGEMENT

Auntie, Kindfull, LymphaTouch, Popit

1. SUPPORTING ECOSYSTEMS AND PLATFORMS

BUSINESS
FINLAND

We promote cutting-edge cancer research, boosting cooperation to develop cancer prevention, diagnostics, treatment and rehabilitation for the best interests of the patients.

CANCER IO

EURO-BIOIMAGING

FICAN MID

FICAN SOUTH

FINGENIOUS

FINBB

FIMM

ICAN

IN FLAMES

KCT



TRANSLATING IMMUNO-ONCOLOGY INTO ACTION

CANCER IO is a cancer immunotherapy-focused collaborative research and innovation project that is part of Business Finland's Personalized Health Program. Cancer IO boosts Finnish immuno-oncology (IO) capabilities by supporting top-level research, business competitiveness, individualization of care and competence in capturing real-world evidence. On a broader level, Cancer IO drives the creation of a Finnish IO ecosystem and national IO growth strategy, aiming to provide wealth and wellbeing through disruptive IO innovations and better care.

Cancer IO brings together a broad range of expertise – from big pharma companies to small enterprises and from academic research to patient advocacy. With a broad range of stakeholders, we can tackle big problems in IO research, real-world data (RWD), clinical care and society.

The project, coordinated by the University of Helsinki, integrates immuno-oncology activities at the Universities of Helsinki and Turku, 4 University Hospitals and one central hospital, all Finnish Cancer Centers, 11 small or medium Finnish enterprises and contract research organizations, several cancer patient organizations and the 12 largest IO-investing pharmaceutical companies. The total number of participants is 38. With a total funding of EUR 10 million, Cancer IO is one of the largest IO-focused research and innovation programs in Europe. Cancer IO's reports can be read on our website cancerio.org.

CONTACT

Juha Klefström
Director

juha.klefstrom@helsinki.fi
+358 44 377 3876
<http://www.cancerio.org>



OPEN-ACCESS IMAGING SERVICES

EURO-BIOIMAGING FINLAND links all major imaging centers from six universities and three university hospitals in Finland into one organization that offers open access to biological and medical imaging technologies and services. In cancer biology and medicine, imaging is used for instance in tumor detection and characterization, and drug development.

Euro-BioImaging Finland provides services in for instance advanced light and electron microscopy, biomedical imaging technologies such as PET, and image data analysis. Euro-BioImaging Finland also participates in the Horizon Europe project canSERV, which provides open access to services dedicated to cancer research.

The benefits of Euro-BioImaging Finland include an individualized, quality-assured approach to cutting-edge imaging, with necessary training and staff assistance to ensure success. Imaging can also be offered as a full service. Collaborations with cancer research groups can also be established.

Euro-BioImaging Finland is part of Euro-BioImaging ERIC (European Research Infrastructure Consortium), a European-wide organization offering open access to biological and biomedical imaging. All services are open to both academic and private sector users, coming from Finland or abroad.

CONTACT

Euro-BioImaging Finland managers:

Pasi Kankaanpää
pasi.kankaanpaa@utu.fi
+358 40 522 1090

Tiina Saanijoki
tiina.saanijoki@utu.fi
+358 50 329 2564

www.eurobioimaging.fi



FOCUS ON INNOVATIVE CANCER RESEARCH AND HIGH-QUALITY CANCER CARE

The regional cancer centre FICAN Mid covers clinical cancer care and cancer research in the Tampere University Hospital and Tampere University region. Health Data Science, comparative effectiveness research and running clinical trials are some of the key focus areas. The core of FICAN Mid, the OECI (Organisation of European Cancer Institutes) accredited Tays Cancer Centre, is an active member in several international collaborations, such as Digicore – the Digital Institute for Cancer Outcomes Research and OECI.

Personalized cancer medicine and molecular profiling, biomarker studies and imaging research are active research areas. In 2019, the University of Tampere and Tampere University of Technology merged to create the new Tampere University. The Faculty of Medicine and Health Technology is dedicated to research in biomedical engineering, biotechnology, medicine and health technology, thus creating an optimal environment for cancer research.

The personnel at the regional cancer centre function both in the University and University Hospital, and serve as easy-to-reach contact points for researchers, business partners and citizens in matters related to cancer care and research.

CONTACT

Annika Auranen

Chief Physician, Director of the regional

cancer centre FICAN Mid

annika.auranen@pshp.fi

+358 50 4704 454

<https://www.ficanmid.fi>



PROMOTING HIGH-QUALITY CANCER CARE AND RESEARCH

THE SOUTHERN FINLAND REGIONAL CANCER CENTER, FICAN SOUTH, coordinates cancer diagnostics and care and promotes cancer research in Southern Finland as well as the aims of the National Cancer Center Finland. Improving cooperation between the professionals in research and clinical work is the most important development target of FICAN South.

To develop our activities, FICAN South has launched several cooperation projects. We work together with several organizations that develop cancer prevention, diagnostics, treatment and rehabilitation, and promote cancer research for the best interests of the patients.

These organizations include the Cancer Society of Finland and its regional organizations and nationwide patient organizations. In addition, we cooperate with trusts promoting cancer research, politicians, officials, research facilities, biobanks, and companies providing digital services, cancer treatments and diagnostics.

CONTACT

ficansouth@hus.fi
www.ficansouth.fi/en



THE FAST TRACK TO BIOBANK SPECIMENS AND BIODATA

FINNISH BIOBANK COOPERATIVE (FINBB) serves cancer researchers worldwide by managing the Fingenious® digital portal, which provides fast access to the high-quality specimens and biodata, including genome data, of Finnish biobanks.

Fingenious® digital service allows researchers to perform quick sample and data queries by browsing biobank collections. Only one feasibility request and one contract via FINBB is needed to reach all public biobanks in Finland, making research through Fingenious® faster and more efficient. Longitudinal health record data, genomic data – mostly as data returned to biobanks from the FinnGen research project, www.finnngen.fi – and information on the possibility of finding specific cancer patients for further biomedical studies can be linked to samples. Fingenious® is built to serve both academic and industry researchers to advance cancer research globally.

FINBB is a cooperative of Finnish biobanks, founded and owned by Finnish universities, hospital districts and the Finnish Institute for Health and Welfare (Terveyden ja Hyvinvoinnin Laitos, THL). FINBB coordinates the operations of the biobank network in Finland and serves researchers by managing the Fingenious® portal that allows access to Finnish biobank specimens and biodata. The company model is value-based: the data generated in scientific studies is returned to biobanks to be used in the further development of treatments.

CONTACT

Marco Hautalahti
CEO

marco.hautalahti@finbb.fi

+358 400 493 613

www.fingenious.fi



R&D FOR PRECISION CANCER MEDICINE

FIMM resources include high-quality patient samples and data repositories, plus the latest research technologies for collaborative projects with public and private sector partners. Partnerships can also include data integration and machine-learning guided digital solutions.

We provide expertise in real-time precision medicine and technologies, such as access to patient samples and anonymized data; patient-derived tumor models and ex vivo drug screening for prioritization of lead compounds and drug repositioning; and phenotypic assays such as multiplexed immunohistochemistry. Further services include next-generation sequencing (NGS) and other comprehensive analyses for biomarker discovery, the identification of new targets for drug development and digital tumor profiling and diagnostics with artificial intelligence-based methods.

FIMM is an academic research institute on the medical campus of the University of Helsinki. Research areas include human genomics, precision cancer medicine, digital diagnostics and population health. FIMM hosts the FinnGen project, a public-private partnership between 10+ global pharmaceutical companies and Finnish biobanks profiling 500,000 Finns, including tens of thousands of cancer patients.

CONTACT

Mari Kaunisto
Senior Researcher,
Communications Coordinator
mari.kaunisto@helsinki.fi
+358 50 317 5483
www.fimm.fi



UNIQUE PAN-CANCER DISCOVERY PLATFORM

iCAN – Digital Precision Cancer Medicine is a national cancer research and competence cluster hosted by the University of Helsinki and Helsinki University Hospital (HUS). The iCAN public-private partnership brings together global leaders and ongoing activities in precision cancer medicine and digital health.

The iCAN flagship project is at the cluster's core and includes an innovative prospective pan-cancer study, which integrates in-depth molecular profiling and drug sensitivity approaches with digital healthcare data into a unique discovery platform. The discovery platform provides breakthrough capabilities and enables the launch of adaptive clinical trials.

iCAN leverages Finnish national strengths and seeks discoveries and improved treatments. Cancer patients are engaged through participation at all stages of iCAN. The iCAN teams have a strong track record in translational and clinical cancer as well as data science, which has generated more than 33,000 citations and over 120 highly cited publications.

CONTACT

Alexandra Gylfe-Liikanen
Business Development
alexandra.gylfe@helsinki.fi
+ 358 405098733
<https://ican.fi>



CANCER: THE SOLUTION IS IN IMMUNITY

InFLAMES Research Flagship, a joint organisation of the University of Turku and Åbo Akademi University, has several research groups focusing on different aspects of cancer. The topics cover a wide spectrum starting from basic research up to clinical trials, patient care, health economics and ethics. New cancer diagnostics and drug development, especially concentrating on the immune system, immunological parameters and tools, are central in the mission of InFLAMES.

InFLAMES has an extensive ecosystem including several organisations, such as Turku Bioscience Centre, Turku PET Centre, Structural Bioinformatics Laboratory, Turku Centre for Disease Modelling, Turku Bioimaging, Drug Discovery Platform, Central Animal Facility and Auria Biobank, as well as several startups and big pharma companies.

InFLAMES offers top-level expertise in a multitude of modern methods utilising the most advanced technology and other infrastructure, disease models and clinical issues.

CONTACT

Sirpa Jalkanen

Flagship Director, Academician of Science

sirpa.jalkanen@utu.fi

+358 40 566 9611

<http://inflames.utu.fi>





INNOVATION AND TRANSLATION IN GENE AND CELL THERAPY

KCT is a research organization based in Kuopio, Finland, focused on developing novel gene and cell therapy products in the new and exciting area of advanced therapeutic medicinal products (ATMPs). Our scientific teams combine scientific know-how gained from years of experience in the sector and the latest technologies to research and develop gene and cell therapy products into Phase I human studies.

We undertake science in collaboration with the private sector and academic groups all over the world. We provide modern facilities for state-of-the-art molecular biology, gene and cell therapy as well as for the extensive range of advanced analytics needed in molecular medicine.

Our goal is to develop new therapies for solid cancers. This requires a deep understanding of the biology of solid tumors, discovery of next-generation gene and cell therapies as well as their preclinical manufacturing and analytical development.

CONTACT

Tuija Kekarainen
Scientific Director
tuija.kekarainen@kct.fi
+358 40 537 6603
www.kct.fi

2. PHARMACEUTICALS, BIOTECH AND RESEARCH

BUSINESS
FINLAND

We help your organization test, research and develop the latest innovations for personalized and effective cancer treatment.

ABOMICS

AURLIDE

BIOVIAN

BRINTER

EUFORMATICS

FARON PHARMACEUTICALS

FINVECTOR

GENEVIA TECHNOLOGIES

ORION

PHARMATEST

TENBORON

TILT BIOTHERAPEUTICS

VALO THERAPEUTICS



GENOMIC MEDICINE EXPERTISE

OUR SOLUTION

ABOMICS specializes in translating genomics research into clinical practice and providing new approaches to personalized medicine. With Abomics GeneRx pharmacogenetic database, Abomics PGx interpretation service and Abomics GeneAccount cloud service, we can offer easily understandable pharmacogenetics services for both physicians and customers on a global scale.

For laboratories, Abomics PGx completes the process workflow of pharmacogenetic testing by delivering a comprehensive pharmacogenetic interpretation report. The service is customizable depending on subscribers' reporting and integration needs. Abomics PGx offers laboratories a unique way to stand out in a highly competitive market and reduces unnecessary organizational costs. The simple yet comprehensive report covers the genetic testing with explanations, a list of drugs with genetic variation and dosing recommendations for each drug.

BENEFITS AND REFERENCES

Personalized medicine has become a reality, and with genetic information, the use of medicine is becoming safer and more efficient. Abomics is a pioneering pharmacogenetic company in Europe, offering services that significantly increase the safety and efficacy of medical treatments. All reports are approved

by various medical professionals who take full responsibility for accurate information.

The reports are easy to read and give specific recommendations based on the information acquired through genetic testing. Abomics collaborates with leading clinical laboratories in Europe.

COMPANY


Abomics was founded in 2013 in Turku, Finland, by two medical doctors, Jari Forsström and Klaus Elenius. Although strong evidence of the merits of utilizing genetic testing in patient care already existed, very few practical applications and decision support tools are available. The fundamental idea behind Abomics is to translate evidence-based research knowledge into clear recommendations that benefit and can be easily understood by both treating physicians and patients.

CONTACT

Jari Forsström
Chief Medical Officer
jari.forsstrom@abomics.fi
+358 40 544 1809
www.abomics.fi



ABOMICS



GENOMIC MEDICINE EXPERTISE

OUR SOLUTION

AURLIDE specializes in the computational discovery of small molecule drug candidates for protein-protein interactions (PPIs), especially related to cancer.

BENEFITS AND REFERENCES

Aurlide speeds up the hit identification stage, quickly optimizing hits to lead compounds. We can rapidly screen millions of compounds to identify drug candidates efficiently. We have developed more than ten first-in-class PPI modulators, participated in the development of four clinical candidates and licensed one of our PPI projects to the pharmaceutical industry.

COMPANY

Aurlide provides services for computer-aided drug discovery, from the identification of first-in-class molecules to lead optimization toward a clinical candidate. Our team holds ten patents and has published more than 100 scientific publications.

CONTACT

Olli Pentikäinen

CEO

olli.pentikainen@aurlide.fi

+358 44 775 2020

www.aurlide.fi



BIOPHARMACEUTICAL MANUFACTURING EXCELLENCE FROM THE TOP OF THE WORLD

OUR SOLUTION

BIOVIAN is an experienced and knowledge-able good manufacturing practice (GMP) producer of recombinant proteins and viral vectors for gene therapy applications, immuno-oncology and vaccines. As a contract manufacturer, Biovian is assigned by clients to develop processes and produce biopharmaceutical molecules for clinical trials as well as for commercial use.

BENEFITS AND REFERENCES

Biovian's concept of a one-stop shop is to provide clients with services through the complete supply and value chain. In other words, all steps in recombinant protein and viral vector production happen under one roof. Since 2005, we have provided viral vector contract development and manufacturing organization (CDMO) services to clients in the EU, the US and Asia. We offer GMP-grade production of adenoviruses, adeno-associated viruses (AAV) and other biosafety level 2 (BSL2) class viruses.

COMPANY

Biovian is a contract development and manufacturing organization that provides premium GMP services to biotech companies developing innovative gene therapies or biopharmaceuticals. Guided by our Nordic ethos, we deliver high-quality work on time and within budget to a global client base.

CONTACT


Antti Nieminen

Director, Business Development and Projects

antti.nieminen@biovian.com

+358 40 502 1332

<https://biovian.com>



PERSONALIZING CANCER CARE THROUGH 3D BIOPRINTING

OUR SOLUTION

Brinter offers an advanced multi-material 3D bioprinter, which is a product of cumulative research and experience from experts in the field. We support life science, pharma and the food industry to develop and disrupt their cutting-edge research and production with complex and user-friendly automation. Our offering is used by universities, hospitals, research organizations, pharma and healthcare companies. Brinter 3D bioprinter is a genuine multi-modular system where the tool heads are customized based on the material and user's need with various dispensing and extruding technologies.

BENEFITS AND REFERENCES

Healthcare is lacking personalization of medication and care. We provide the tools to serve individual needs with mass customization capabilities.

We have supported the development of personalized medicine and drugs for the Pharmaceutical industry. We have also built applications that

support diagnostics of specific cancer types – also in drug testing and development. In other words, we support diagnostics, improve drug discovery and do it on a personal level.

COMPANY

Brinter is a Finnish bioprinting company. We provide comprehensive 3D bioprinting solutions and services for the pharmaceutical, life science and healthcare industries.

CONTACT

Pasi Kaskinen

CEO

pasi.kaskinen@brinter.com

+358 50 575 7577

www.brinter.com

The screenshot displays the omnomicsNGS software interface. The top navigation bar includes the logo and the identifier 'HD778_b38_SNV_InDel_CNV'. A sidebar on the left contains navigation options: Home, Patient, Sample, Current Excerpt, Workbench, ASCO Report, Saved Reports, Checklist, Functional log, Interpretations, and Cohorts. The main content area shows a 'Reported variants' section with a search bar and filters. Below this is a table of variants with columns for Gene/Variant, Assessment Status, Classification ACMG, ASCO/AMP Tier, Consequence, and Chr:p.

Gene/Variant	Assessment Status	Classification ACMG	ASCO/AMP Tier	Consequence	Chr:p
Gene: EGFR					
Gene/Variant	Not assessed	Uncertain significa...	II	missense_variant	chr7:5
Gene: KIT					
Gene/Variant	Not assessed	Benign	II	missense_variant	chr4:5
Gene/Variant	Not assessed	Uncertain significa...	II	missense_variant	chr4:5
Gene: KRAS					
Gene/Variant	Not assessed	Likely pathogenic	II	missense_variant	chr12:
Gene: ALK					
Gene/Variant	Not assessed	Uncertain significa...	III	stop_gained	chr2:2

Demo instance 4 - GRCH38, 2.8.1

ACCELERATING THE TRANSITION TO PRECISION MEDICINE

OUR SOLUTION

Molecular pathologists and geneticists use the Euformatics software for identifying known actionable or potentially causative variants from NGS-based gene testing. The modular software addresses testing validation, quality control, and genomic variant annotation, classification, interpretation, and reporting. The CE-IVD software supports laboratories from small to very large.

BENEFITS AND REFERENCES

The robustness of the omnomicsQ validation, verification, and quality control management provides the highest confidence in results that a molecular genetics diagnostic laboratory can deliver; quality is no accident. The flexibility of the architecture of omnomicsNGS for genomic analysis and reporting enables adaptation to diverse laboratory requirements. Standard formats -based application programming interfaces (API) facilitate integration into larger clinical diagnostic and research systems.

REFERENCES

Alife (CO), EMQN (UK), GenQA (UK), HUSlab

(Finland), Instand-NGS4P (EU), KCMH (TH), Queen Mary Hospital (HK), Synlab (CH) and Unilabs (CH).

COMPANY

Euformatics is a technology driven company developing software for clinical gene testing, for microbiome analysis, and for infectious disease surveillance. The company works tightly with sequencer and kit providers as well as external quality assessment bodies. We aim at further widening the scope of our partnerships with companies developing and using NGS.

CONTACT


Tommi Kaasalainen

CEO

tommi.kaasalainen@euformatics.com

+358 50 4861210

<https://www.euformatics.com>



THE FUTURE OF IMMUNOTHERAPY

OUR SOLUTION

Bexmarilimab (formerly Clevegen) is Faron's wholly owned, investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid cell function. Bexmarilimab, a novel anti-Clever-1 humanised antibody, targets Clever-1 positive tumour associated macrophages in the tumour micro-environment, converting these highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages. Bexmarilimab has the potential to be the first macrophage immune checkpoint therapy. To date, the investigational therapy has been shown to be safe and well-tolerated, making it a low-risk candidate for combination with existing cancer therapies, and has demonstrated early signs of clinical benefit in patients who have exhausted all other treatment options.

BENEFITS AND REFERENCES

While the arrival of currently available checkpoint inhibitors has been one of the most exciting breakthroughs in cancer care, their low response rate in most tumour types continues to hinder their clinical application. Our biomarker analysis shows that the tumours of patients benefiting from bexmarilimab treatment expressed low levels of PD-L1 - a patient group that generally does not receive benefit from or is ineligible for treatment with currently approved

checkpoint inhibitors. There remains an urgent need for effective new treatment options, including novel assets that work synergistically with existing checkpoint inhibitors to ignite and amplify the patient's immune response. Bexmarilimab may serve as a catalyst for the immune system allowing initially checkpoint inhibitor resistant or ineligible patients to become responsive to PD-1 blockade.

COMPANY

We are a clinical stage biopharmaceutical company and ever since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Our focus is on our core scientific and clinical development expertise and advancing our broad pipeline of novel programs including Bexmarilimab in oncology, Traumakine in organ protection and Haematokine in regenerative medicine. Faron works today with tomorrow's breakthroughs.

CONTACT

Juho Jalkanen
Chief Operating Officer
juho.jalkanen@faron.com
+358 40 707 1046
www.faron.com





PIONEERS IN VIRAL-BASED GENE THERAPY PRODUCTS

OUR SOLUTION

FINVECTOR is a world leader in R&D and current good manufacturing practice (cGMP) of viral-based gene therapy products. Our state-of-the-art facility – with four cGMP suites – is equipped with the latest technology, highly experienced scientific team and our commitment to work closely with clients every step of the way. This has helped us build an excellent reputation in the gene therapy market. We are authorized under the European Medicines Agency (EMA) for the production of gene therapy products for clinical and commercial supply.

BENEFITS AND REFERENCES

Importantly, leveraging our scientific expertise and industry knowledge gained through the development of our own and our clients' products, we can help take viral-based products from the preclinical phase through clinical trials and to the global market. Our global clients range from big pharma to spinout biotech companies. FinVector's track record of delivering a tailored service to meet and exceed our clients' needs goes back two decades when Professor Seppo Ylä-Herttuala formed the company back in 1993. We know that the job we do represents a competitive advantage for our partners.

COMPANY

FinVector offers contract manufacturing services across a wide range of viral vector-based product types, including adenoviral, adeno-associated virus (AAV) and lentiviral-based vectors, utilizing suspension and adherent-based platforms. From our cutting-edge fully licensed GMP manufacturing facilities in Finland, we have built an extensive pipeline of gene therapy products and technologies for our clients and in-house products. The team at FinVector is passionate about delivering excellence for our global clients, and we look forward to working with new and existing partners in the years to come.

CONTACT

Kassim Kolia

Head of Business Development

kassim.kolia@finvector.com

+44 77 95 06 53 36

www.finvector.com





THE NEW STANDARD FOR BIOINFORMATICS

OUR SOLUTION

Genevia Technologies The key cause of malignancies lies in altered genomic information. Our mission is to help understand the causes and effects of cancer-causing mutations and contribute to the development of personalized medicines. Genevia Technologies provides cancer researchers and oncologists with an easy way of understanding their high-throughput data and accessing relevant information in public data repositories. Our support can include bioinformatics consulting, next-generation sequencing (NGS) experiments in collaboration with the best service providers and top-quality data analyses. Our bioinformatics team is specialized in highly customizable projects that can include combining high-throughput data from all measurement platforms, integrative analyses and modelling.

BENEFITS AND REFERENCES

For many researchers and companies, the data analysis stage becomes a significant hurdle as technologies advance. Our services cover everything from an urgent need in basic analysis to building customized user-friendly solutions for continuous use. Our data analysis services cover various biological data types, such as NGS, proteomics and microarrays. We also support those who are only discovering the field of cancer genomics. We work in teams of dedicated data scientists and biologists and are therefore able to provide results with fast turn-around times without compromising on scientific quality. Our expertise spans bioinformatics education and writing relevant sections of grant applications.

Projects may include a combination of expert consulting, bioinformatics pipeline development and analysis of sequencing data followed by support in disseminating the results. If you require only a bioinformatician in your team, we can be flexibly contracted as external team members. Our clients are mainly pharmaceutical companies, molecular diagnostics providers, industrial biotechnology and life science research groups.

COMPANY

Genevia Technologies has assembled a team of bioinformaticians, biologists and software engineers to disseminate the latest data analysis methods and bioinformatics know-how to all sectors of life science. We believe that the combination of high-throughput measurements, like NGS, and well-designed analyses can bring benefits to all life science research and development projects. Genevia is a Finnish bioinformatics company established in 2011 as a spin-off enterprise from the Tampere University of Technology by Professor Matti Nykter.

CONTACT

Antti Ylipää, CEO & Co-Founder
antti.ylipaa@geneviatechnologies.com
+358 40 747 7672
www.geneviatechnologies.com



NOVEL DRUGS FOR CANCER TREATMENT

OUR SOLUTION

Oncology is one of ORION'S core therapy areas in pharmaceutical R&D. Our goal is to develop new and effective therapies to treat solid cancers. Our scientists are committed to understanding the underlying mechanisms of a patient's disease and use this information in the discovery of treatments. This requires comprehensive use of genetic and molecular data of solid tumors and addressing both the intrinsic and extrinsic (immune cell) mechanisms that drive tumor growth and treatment resistance.

BENEFITS AND REFERENCES

Orion's first proprietary drug for breast cancer has been on the market already since 1988. Darolutamide, a compound discovered by Orion, is an antiandrogen medication used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is approved in more than 60 markets around the world. The addition of darolutamide to androgen-deprivation therapy and docetaxel is associated with a significant overall survival benefit in patients with metastatic hormone-sensitive prostate cancer, according to

results of the phase 3 ARASENS trial. The compound is currently being investigated in further studies across various stages of prostate cancer. Orion has also expanded its research activities to include also other types of cancer.

COMPANY

Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of Orion's pharmaceutical R&D are oncology, pain and respiratory diseases for which Orion develops inhaled pulmonary drugs. Orion's net sales in 2021 amounted to EUR 1,041 million.

CONTACT

Outi Vaarala

Senior Vice President for
Research and Development

outi.vaarala@orionpharma.com

+358 50 966 3472

www.orion.fi/en



Building well-being



SERVICES FOR THE PHARMACEUTICAL INDUSTRY

OUR SOLUTION

PHARMATEST offers preclinical in vitro and in vivo efficacy models in the fields of oncology and skeletal diseases. Let our experts with their well-established models in oncology and skeletal diseases reveal the potential of your compound as early as in the preclinical phase. In oncology, we have special expertise in orthotopic and bone metastasis models, immuno-oncology and radiopharmaceutical testing.

BENEFITS AND REFERENCES

All research is performed at modern in-house laboratories by our committed specialists with exceptionally strong scientific and technical expertise in preclinical models of oncology and skeletal diseases. Our carefully validated and optimized models have high clinical predictivity to save your time and costs. During the past 20 years, we have served more than 100 clients globally by testing thousands of their compounds.

COMPANY

Founded in 1998, Pharmatest is a flexible organization with acknowledged expertise, fast turnover times and active communication. We provide efficient and high-quality customer experiences. Today, Pharmatest looks into the future of changing the pharma environment with strong optimism. Our goal is to become the leading provider of specialized preclinical disease models and efficacy-related research services.

CONTACT

Jukka Rissanen

CEO

jukka.rissanen@pharmatest.com

+358 50 380 9551

www.pharmatest.com



BORON NEUTRON CAPTURE THERAPY

OUR SOLUTION

TENBORON Boron neutron capture therapy (BNCT) is biochemically targeted radiotherapy. Boron neutron capture reaction leads to intense local irradiation precisely at the site of boron accumulation, which leads to tumor necrosis. The Boron-10 (^{10}B) atoms are selectively delivered to the tumor, followed by irradiation with epithermal neutrons (nth). A nuclear reaction occurs when a ^{10}B atom captures a neutron. The short-range reaction products restrict most of the radiation dose to the boron-loaded cells.

BENEFITS AND REFERENCES

Compared to many other cancer treatment modalities, BNCT is less invasive and affects healthy tissues less than conventional radiation therapy, has fewer side effects and can be used in combination with other treatments. In previous studies, BNCT has been curative for 15–20% of terminal-phase patients, despite using a sub-optimal boron carrier.

It can be used to treat many kinds of solid tumors that can be boron loaded. What's more, the treatment method has been proven cost effective. In the majority of cases, it requires only a small number of treatment sessions and shorter hospital periods.

COMPANY

Tenboron began the development of novel boron carriers in 2012. The lead compound has shown very good efficacy and a favorable safety profile in preclinical studies. It will be entering the clinical development phase in 2021. The company is a privately held SME headquartered in Helsinki.

CONTACT

Juha Jouhki

CEO

juha.jouhki@tenboron.fi

+358 500 843 843

www.tenboron.fi



ADVANCED ONCOLYTIC IMMUNOTHERAPY

OUR SOLUTION

TILT BIOTHERAPEUTICS is a clinical-stage biotechnology company developing oncolytic immunotherapies against a range of cancers including ovarian, head & neck, and lung.

BENEFITS AND REFERENCES

The company's patented TILT® technology – delivered locally and systemically – modifies the tumor microenvironment and eliminates its ability to suppress immune responses to cancer. This enhances T-cell therapies such as immune checkpoint inhibitors and CAR-T therapies. TILT's lead asset, TILT-123, is an oncolytic adenovirus armed with two human cytokines – TNF alpha and IL-2.

TILT-123 has demonstrated a 100% response rate in preclinical cancer models in vivo. It is currently in several Phase 1 clinical trials in Europe, the U.S. and China. The company's pioneering approach has been recognized by industry leaders, including Germany-based Merck KGaA and the US-based Pfizer, who are collaborating to investigate TILT-123's therapeutic effect in combination with the PD-L1 inhibitor, Avelumab (Bavencio®), in clinical trials.

In 2019, TILT established a partnership with Biotheus, a privately held Chinese company, for the development and commercialization of TILT's proprietary oncolytic virus TILT-123 in Greater China.

COMPANY

The leadership team of TILT Biotherapeutics includes its CEO Akseli Hemminki, a biotech entrepreneur and cancer clinician who has personally treated almost 300 patients with ten different oncolytic viruses. Akseli leads a team of experienced industry professionals who collectively have decades of experience in the development and commercialization of cancer therapeutics. TILT Biotherapeutics has funding from Lifeline Ventures, Tesi, angel investors, Business Finland, and the European Innovation Council (EIC).

CONTACT

Aino Kalervo
CBO

aino.kalervo@tiltbio.com

+358 50 321 7454

www.tiltbio.com





REINVENTING CANCER IMMUNOTHERAPY

OUR SOLUTION

VALO THERAPEUTICS Immunotherapies have revolutionized the treatment of cancer. PeptiCRAd, an innovative cancer immunotherapy technology developed by Valo Therapeutics, makes tumors visible to the immune system. It provides a tailor-made solution for every patient to destroy cancer. PeptiCRAd treatment is highly flexible and adaptable to each patient's cancer. The treatment activates the immune system to detect and destroy cancer cells everywhere in the body.

BENEFITS AND REFERENCES

PeptiCRAd is a highly versatile plug-and-play immunotherapeutic platform, which can be tailored to target any class of tumor antigens and triggers unparalleled T-cell responses against multiple tumor targets. Immunotherapy with checkpoint inhibitors provides dramatic outcomes in approximately 20% of patients.

Valo's PeptiCRAd platform offers the potential to expand this target population of patients by creating appropriate anti-tumor immune responses that can be unleashed by checkpoint inhibition.

COMPANY

Based in Helsinki, Valo Therapeutics develops novel immunotherapeutic platforms to treat solid tumors. The lead platform, PeptiCRAd, combines the immunostimulatory potential of oncolytic adenoviruses with the tumor specificity of peptide vaccines to create unparalleled anti-tumor immune responses. Its first pipeline product will be available in clinics in early 2021.

CONTACT

Scott Cuthill

Chief Business Officer

scott.cuthill@valotx.com

+44 78 1543 7932

www.valotx.com



VALO
THERAPEUTICS

3. DIAGNOSTICS, TESTING AND SCREENING

BUSINESS
FINLAND

We create customizable screening and diagnostic solutions for improved treatment, increased analysis accuracy and patient comfort.

BIOPSENSE

BLUEPRINT GENETICS

FINNADVANCE

LS CANCERDIAG

MEGIN

MISVIK BIOLOGY

MYLAB

OLFACTOMICS

OPTOMED



SOLUTIONS FOR LESS-INVASIVE GENETIC ANALYSES

OUR SOLUTION

BIOPSENSE offers solutions and services for liquid biopsy monitoring of cancer mutations. Services include blood cell-free DNA extraction, quantitation and genetic analysis – based on the polymerase chain reaction (PCR) technique and mass spectrometry. Both large cancer panels validated by Agena Bioscience and in-house customized panels are available for monitoring. Customized panels enable follow-up of patients with economical pricing.

BENEFITS AND REFERENCES

Screening for cancer biomarkers with BiopSense is an effective way to optimize cancer treatments. Frequent monitoring of patients helps oncologists optimize the treatment and find drug resistance far before scanning can be performed. As a result, patients receive the correct treatment faster.

Oncologists have also used the trend in the cell-free DNA (cfDNA) number as an indicator of cancer progression.

COMPANY

BiopSense was born out of a university research project in 2018 to offer solutions for oncologists and researchers. The company has a committed core team with extensive expertise in molecular biology, nanoscience and oncology. Besides offering diagnostic services, BiopSense develops novel pre-analytical technologies.

CONTACT

Veli-Mikko Puupponen

CEO

info@biopsense.com

+358 40 658 7785

www.biopsense.com



HIGH-QUALITY GENETIC TESTING

OUR SOLUTION

BLUEPRINT GENETICS combines advanced genetic testing with actionable genetic knowledge to provide the most comprehensive diagnostics for all medical specialties, including hereditary cancer. Genetic testing is the most effective way to identify individuals with a genetic predisposition toward developing cancer. Knowing the inherited genetic defect can be useful when planning the treatment or follow-up of both unaffected and affected family members. We offer comprehensive and customizable testing for several disorders associated with hereditary cancer susceptibility.

BENEFITS AND REFERENCES

We believe in transparent, high-quality genetic diagnostics to drive the promise of precision medicine forward. Anything we can do to improve and speed up diagnosis not only allows us to plan the best and most cost-effective treatments but also plays an important part in patient comfort and long-term prognosis.

This is where genetic testing can truly make a difference. With a customer base spanning over 70 countries, we work with close to 5,000 clinicians all over the world.

COMPANY

Blueprint Genetics is a leading specialty genetics and bioinformatics company focused on inherited diseases. With a patient-first mindset, we deliver high-quality genetic testing to the global clinical community. By combining a state-of-the-art laboratory process, the latest sequencing technology, AI-empowered data-crunching tools and techniques, world-class professionals and a holistic customer experience approach, we are leading the way in changing the mainstream healthcare of tomorrow.

CONTACT

Thomas Borge

Sales Director


tb@blueprintgenetics.com

+47 92 63 45 02

www.blueprintgenetics.com

Blueprint Genetics





MICROFLUIDICS AND MICRITECHNOLOGY SOLUTIONS

OUR SOLUTION

FINNADVANCE In the human body, cells with different mechanical properties form different tissues. These mechanical cues in the local cell environment give rise to the unique biochemical response either via extracellular matrix (ECM) production or by cell signaling. In routine cell biology studies, cells are grown on various surfaces like polypropylene, polystyrene and glass. It has been long known that the cell morphology observed in vivo is not reflected in these culture conditions. We grow physical avatars of human diseases in miniature chips. They are composed of silicon chips where human cells are grown. These disease-on-chips will be used for discovering a cure for rare diseases and lead to better-personalized medicines.

BENEFITS AND REFERENCES

Finnadvance focuses on in vivo-like biology, with dense cell populations, perfusion and mechanobiology controls. The company's microfluidic approach enables complex co-cultures with precise control of flow velocities and 3D ECM stiffness, without requiring extensive initial biomaterial and replicating precise bio-mechanical stimuli in vitro. Using our microfluidic culture systems, we aim to close the gap between

in vitro studies and in vivo results. Our devices are fully integrated microfluidics solutions compatible with microscope and imaging systems.

We undertake custom chip design and fabrication projects for specific applications. Challenge us!

COMPANY

Finnadvance is an Oulu-based microtechnology startup leveraging organ-on-chips for faster drug R&D. Among other things, we specialize in tailored hardware solutions and biomaterials for cell culture and microfluidic design and fabrication. We have 7+ years of experience in microtechnology, biomaterial fabrication and testing. Finnadvance has in-house engineering and production facilities.

CONTACT

Prateek Singh

CEO

science@finnadvance.com

+358 40 653 7049

www.finnadvance.com



finnadvance



DETECT LYNCH SYNDROME TO PREVENT CANCER

OUR SOLUTION

Lynch syndrome is the most common inherited cancer predisposition with a prevalence of 1 in 279. LS CancerDiag has developed DiagMMR®, a unique functional test to simply and accurately detect whether a person has an inherited mismatch repair (MMR) deficiency, the hallmark of Lynch syndrome. Finding high-risk individuals and families early improves health outcomes, saves lives and dramatically reduces healthcare costs.

BENEFITS AND REFERENCES

DiagMMR® finds inherited functional defects with superior accuracy and before cancers develop. As a predictive tool, it provides critical insights for adequate clinical decisions. Clinicians only need to take a minute skin biopsy and send it to our testing laboratory to receive an easy-to-understand and actionable result. This enables preventive treatment and personalized care. DiagMMR® is a CE marked in vitro diagnostic medical device (IVD MD), commercially available in Finland and being piloted with laboratories abroad.

COMPANY

LS CancerDiag is a spin-off from the University of Helsinki. Our team is a winning combination of academic and business leaders who brought DiagMMR® from lab to market and built a global patent portfolio covering 29 countries in Europe, North America, and Asia. Most recently, the company's quality management system was ISO 13485 certified. We are now actively looking for partners to bring our solution to the US market.

CONTACT

Philippe Arnez
Chief Business Officer
philippe.arnez@lscancerdiag.com
+358 40 627 8555
www.lscancerdiag.com



A DYNAMIC VIEW OF THE HUMAN BRAIN

OUR SOLUTION

MEGIN Magnetoencephalography (MEG) is a completely non-invasive functional brain mapping technology for diagnostics and guidance of the treatment strategy, including interventions for neurological conditions.

BENEFITS AND REFERENCES

Combined with magnetic resonance imaging (MRI), MEG can support the neurosurgeon or radiation oncologist in assessing the likely impact of a planned therapy on motor ability, sensory responses and language processing. In brain tumor patients who also have convulsions, MEG provides accurate and precise location information of areas responsible for the seizures. Thorough research and dedicated exploration of the endless possibilities with MEG have allowed specialists around the world to study pathological and eloquent areas of the brain in patients diagnosed with neurological disorders.

COMPANY

MEGIN Oy is a neuroscience technology company based in Helsinki, Finland. The company is focused on developing innovative solutions for functional brain imaging for the presurgical evaluation of patients with epilepsies, brain tumors or other brain lesions. For over 30 years, MEGIN has been the global leader in magnetoencephalography technology. The company's latest TRIUX™ neo-MEG system offers a non-invasive, real-time view of patient-specific neural activity with millimeter accuracy and millisecond resolution, providing the most precise information available on the market today.

CONTACT


Miikka Putaala

Director, Business Development

info@megin.fi

+358 9 756 2400

www.megin.fi



TRANSFORMING RARE CANCER CARE

OUR SOLUTION

MISVIK BIOLOGY About 22% of newly diagnosed cancers are rare cancers, making them the most common cancer as a group. There are very few approved targeted therapies for any rare cancer, and the low numbers of cases limit clinical development of novel treatments. Alternative approaches are urgently required to allow clinical development of new therapies for rare cancers. Our solution is a unique diagnostic test for rapid assessment of patient and cancer type-specific therapy efficacy to support precision medicine in rare cancer care.

BENEFITS AND REFERENCES

Our service is a powerful diagnostic tool for the stratification of rare cancer patients beyond genetic biomarkers to targeted therapies. It also supports a systems biology approach to understand and define drug efficacies in different human cancers.

It can be used to increase the effective treatments of individual patients, reduce costs of ineffective cancer therapies, as well as identify exceptional responders and indications for new drugs.

COMPANY

Built upon two decades of expertise in high-throughput biology, Misvik's TrialTest™ platform integrates state-of-the-art omics technologies for functional drug efficacy testing. To demonstrate successful profiling of the patient, cancer and cell type-specific drug efficacies, Misvik together with Docrates Cancer Hospital, Finnish University hospitals and the pharma industry have tested the method with hundreds of drugs and more than 50 different human cancer types.

CONTACT

Juha Rantala
CEO, Principal Investigator
rantala@misvik.fi
+358 400 151 584
www.misvik.com



DELIVERING LIFE BY DELIVERING DATA

OUR SOLUTION

MYLAB'S My+®, My+ care® and My+ hub® application and integration solutions enable clinical laboratories to provide accurate and timely diagnostic data to their customers for better healthcare. Developed jointly with our customers, these solutions are provided as a service to bring people, solutions and data together.

COMPETITIVE ADVANTAGE

Spanning all laboratory specialties, including pathology, My+® is the end-to-end solution for clinical laboratories, such as the Helsinki University Hospital (HUS) Diagnostic Center. The digital workflows, reinforced with AI, ensure fast and accurate cancer diagnostics. At HUS, the combined human papillomavirus (HPV) and pap test service allows efficient mass screening of cervical cancer. In cancer care, the results delivered by our messaging service ensure that chemotherapy can be carried out as planned and support post-treatment prostate-specific antigen (PSA) follow-up for care units and patients.

COMPANY

Mylab is the leading Finnish supplier of healthcare, clinical laboratory and diagnostics information systems in Finland. We place a high value on human life. By implementing better and more reliable technological solutions for healthcare use, we support long, healthier lives of better quality.

CONTACT

Taru Honkonen
Marketing Manager
taru.honkonen@mylab.fi
+358 10 678 6021
www.mylab.fi



CANCER DIAGNOSTICS OF THE FUTURE

OUR SOLUTION

OLFACTOMICS develops gas sensor-based solutions for medical and life science applications. IonVision™ is a research device used to study compounds that are responsible for odors related to a disease. Resect™ is a medical device under development that assists surgeons with more accurate cancer surgery.

COMPETITIVE ADVANTAGE

The ability of dogs to detect various diseases from cancers to COVID-19 has been well documented. Still, bringing dogs to a clinical practice remains a challenge. IonVision™ is a user-friendly alternative, providing the same diagnostics capabilities achieved by dogs. By leveraging proven differential mobility spectrometry technology with the latest data analytics, Olfactomics IonVision™ provides a cost-effective and user-friendly method to analyze gas mixtures and odors. It is currently being adopted by several universities in Europe, and interest is growing worldwide.

COMPANY

Olfactomics was founded by a team of engineers and clinicians from Tampere University in 2015. A scientific approach remains a core value of the company. The company has an ISO 13485-certified quality management system and is headquartered in Tampere.

CONTACT

Antti Roine

CEO

info@olfactomics.fi

+358 40 841 0698

www.olfactomics.fi



INNOVATIVE SCREENING SOLUTIONS

OUR SOLUTION

OPTOMED is a leading provider of process management software for cancer screening in Northern Europe. We offer our customers efficient tools to optimize breast, cervical and bowel cancer screenings. The screening software is modular, so it can be modified to fit the needs of different healthcare units. The solutions have helped screening operations become available both in nationwide operations as well as in small standalone clinics.

COMPETITIVE ADVANTAGE

Our solutions improve patient care by increasing the quality of operation and accessibility of screening services. The software saves time and costs for healthcare units. It also standardizes reporting and statistics according to international screening guidelines. When Finland's national breast cancer screening operations moved from film to imaging 15 years ago, our solutions helped digitalize and centralize operations, improving operational quality and saving personnel costs.

Today, our solutions help several competing laboratories in Finland run their cervical cancer screening operations efficiently.

COMPANY

Founded in Oulu, Finland, in 2004, Optomed is an experienced high-security information system provider. Our screening software is designed with a focus on data protection and other healthcare sector privacy and regulatory requirements.

CONTACT

Markku Myllylä

Vice President, Software Solutions

markku.myllyla@optomed.com

+358 400 459 778

<http://www.optomed.com>

4. DIGITAL CANCER SOLUTIONS

BUSINESS
FINLAND

We build and deliver the latest cancer care technologies and turn PROM data into action boosting the individualization of care.

ADESANTE

AIFORIA

BC PLATFORMS

BUDDY HEALTHCARE

GRUNDIUM

INNOMENTARIUM

KAIKU HEALTH

MEDISAPIENS

PLANMED

VARIAN MEDICAL

VEIL.AI



ZERO SURGICAL FAILURES

OUR SOLUTION

ADESANTE'S SurgeryVision is a planning tool for cancer surgery that allows the surgeon to examine a patient's magnetic resonance imaging (MRI) / computed tomography (CT) images in virtual reality (VR) and plan the surgical procedure directly into a 3D stereoscopic model.

COMPETITIVE ADVANTAGE

SurgeryVision shows image data in 3D stereoscopic format to help surgeons better understand it. The surgery plan can be shown in the operating theater during the procedure, helping surgeons stay on track throughout the operation. This helps reduce near-miss events, surgical failures and even the need for repeat operations.

COMPANY

ADESANTE is a Finnish healthcare IT company established in 2017. The company operates through its distributor network in Europe, the Middle East and Asia.

CONTACT

Petteri Joenpolvi
CEO

info@adesante.com

+358 400 012 392

www.surgeryvision.com



AI-POWERED ANALYSIS IN PATHOLOGY

OUR SOLUTION

AIFORIA provides a first-in-class, versatile, cloud-based platform and services for medical researchers, clinicians and pharmaceutical R&D scientists working across different areas of oncology. We help automate image analysis tasks involved in studying and evaluating samples from a variety of cancers using artificial intelligence. This increases the speed, accuracy and consistency of analyzing large and complex medical images in oncology.

COMPETITIVE ADVANTAGE

With the prevalence of cancer increasing, many countries have a shortage of pathologists. This results in delays in analyzing samples and postpones access to treatment. Also visual methods for evaluating these diseases and their accompanying samples are subjective, and the interpretations of samples can vary. Using our AI improves efficiency. AI models built by or with Aiforia can automate time-consuming image analysis tasks when studying different types of cancers. Tasks can include automating the quantification of certain biomarkers like PD-L1 or tumor grading in lung cancer biopsies.

As an example, an MIT lab studying lung cancer in mice was manually interpreting its samples, counting cells and measuring tumors by eye.

This was not only prone to bias but also incredibly laborious. By using artificial intelligence, the researchers were able to automate and standardize the evaluation, giving them not only more accurate results but more time to focus on other important cancer research tasks. Accuracy and consistency are increased with our AI software. Our AI models analyze samples and images consistently, removing the bias often experienced by pathologists and organizations studying different oncology samples.

COMPANY

We are a comprehensive mix of experienced life-science entrepreneurs and research pioneers in the field of cloud-based microscopy and pathology. Founded in 2013, Aiforia Technologies is a spin-off company from the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki.

CONTACT

Emma Vehviläinen, Head of Marketing
emma.vehvilainen@aiforia.com
+358 40 667 5204
www.aiforia.com





PLATFORM FOR PERSONALIZED MEDICINE

OUR SOLUTION

BC PLATFORMS is a global leader in providing a powerful data and technology platform for personalized medicine, accelerating the translation of insights into clinical practice. Our technology drives the infinite loop between personalized care and research discoveries, leveraging the latest science, deep technical expertise, strategic partnerships and harmonized, diverse data collections.

COMPANY

BC Platforms has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, clinicians, developers, manufacturers and vendors. The company focuses on addressing some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies

CONTACT

Anna Wozniak

EVP, Strategy and Development


anna.wozniak@bcplatforms.com

+41 44 562 03 87

www.bcplatforms.com

COMPETITIVE ADVANTAGE

Our high-performing configurable data discovery and research platform enables flexible data integration, secure analysis and interpretation of harmonized genomic and clinical information. The platform offers enhanced interoperability with a suite of seamlessly integrable modules for a tailored deployment. This end-to-end technology accelerates the translation of research insights into clinical practice, enabling personalized medicine. To learn more, click here: info.bcplatforms.com/white-paper-advancepersonalizedmedicine





AUTOMATING SURGICAL CARE PATHWAYS

OUR SOLUTION

BUDDY HEALTHCARE produces intelligent and automated surgical care pathways that can be used, for example, to manage and monitor patient activities related to oncological surgeries. A patient-facing mobile app allows healthcare professionals to guide, manage and inform their patients with the right information at the right time. With the BuddyCare clinical dashboard, care personnel has real-time, at-a-glance visibility of their patients' activities and an overview of the process. The patient-generated and visualised data enables care teams to triage patients and intervene sooner at early signs of declining engagement, potential no-shows, cancellations, or other challenges. The platform collects patient data, such as pre-assessment forms or submitted patient-reported outcome measures and experience measures (PROMs and PREMs). The platform generates reports for hospital management.

COMPETITIVE ADVANTAGE

More than 50 European clinics already automate care coordination and patient communication processes with the platform. Hospitals that have implemented the platform have seen a 98% reduction in preoperative phone calls to patients, over an hour less in preoperative time spent

per patient, and even a 50% reduction in surgery patients' no-shows or cancellations.

COMPANY

A European-based digital health company, Buddy Healthcare, helps implement the best possible care pathways and forms an effortless communication link between home and hospital. The company was founded in 2016, and its platform was co-created in collaboration with university hospitals. The company's platform is currently in use in Europe, focusing on Finland, Germany, and the UK. The BuddyCare software has the Medical Device Class I CE mark and is GDPR and HIPAA compliant. Also, the company's QMS is ISO 13845:2016 Certified.

CONTACT

Pipsa Karioja
Marketing Manager
pipsa@buddyhealthcare.com
+358 40 216 4930
www.buddyhealthcare.com





THE WORLD'S MOST PRACTICAL MICROSCOPE SCANNER

OUR SOLUTION

GRUNDIUM removes the entry barrier to digital pathology with the world's most practical microscope scanners. With its sharp scanning, small footprint, ease of use, affordable cost and overall sensibility, an Ocus® in your lab helps you make the best professional diagnosis available for all life.

COMPETITIVE ADVANTAGE

The patented, innovative Grundium Ocus imaging system takes the sharpest images in digital pathology. It is very easy to use – a new user can be trained in only 15 minutes. A Grundium Ocus system costs only a fraction of a multislide scanner, making it remarkably affordable. Designed and built for telepathology, Grundium Ocus makes remote work simple and easy. It fits any workflow by supporting most file formats and the Grundium API ensures seamless integration with any system.

COMPANY

Grundium is a global leader in advanced imaging technology. Established in 2015 by ex-Nokia engineers, the Tampere-based company is democratizing digital pathology with the Ocus microscope scanners. The cutting-edge imaging solutions are based on over 20 years of experience in optics, sensors and processing. Grundium serves various industries and businesses by enhancing quality and processes, protecting human life and safeguarding a clean environment.

CONTACT

Mika Kuisma

CEO

mika.kuisma@grundium.com

+358 50 354 6952

www.grundium.com



BREAST CANCER SCREENING GOES DIGITAL

OUR SOLUTION

INNOMENTARIUM has developed the FeniX solution to update analog mammography devices for the digital age. Based on decades of experience, the FeniX solution extends the lifecycle of machines for years to come, reliably and without compromising quality.

COMPETITIVE ADVANTAGE

FeniX is the result of a substantial development project in which the existing mammography machine receives a new heart in the form of direct digital technology. Thanks to usability studies conducted during the development project, the digitally updated Performa imaging system is easy to use, safe and effective – for both radiographers and patients. The full integration of an existing mammography device with the FeniX solution has been verified, and the image quality has been clinically tested. The new solution meets all the necessary standards and requirements. The cost effectiveness and ecology of the design highlight our responsibility.

COMPANY

Innomentarium is a privately owned Finnish health-tech company established in 2010 with business activities beginning in 2014. Even though we are a young company, our team has decades of experience in the health-tech business and medical imaging. We have harnessed our know-how to research and develop new ways of imaging, creating qualified and affordable solutions for medical imaging professionals. The company is based on the Oulu University Hospital campus in Finland and has a branch office in Helsinki.

CONTACT

Jouni Ihme

Founder & CEO

jouni.ihme@innomentarium.fi

+358 400 689 824

www.innomentarium.fi





DIGITAL HEALTH INTERVENTIONS FOR CANCER PATIENTS

OUR SOLUTION

KAIKU HEALTH is a digital health intervention platform for cancer clinics. It provides patient-reported outcome monitoring and intelligent symptom tracking. With the use of the Kaiku Health platform, cancer clinics can provide optimized care through timely symptom management and improved workflow.

COMPETITIVE ADVANTAGE

Kaiku's unique algorithms screen symptoms, alert care teams and provide support for cancer patients. Along with the capture and analysis of real-world data, this paves the way for more personalized and value-based healthcare. Kaiku Health is used to capture and process data for all common cancer types.

COMPANY

Kaiku Health is a digital health company aiming to improve cancer patients' quality of life through health data science. Our digital health intervention platform has modules for over 25 cancer types across different cancer care pathways. It is currently in use in over 40 European cancer clinics and hospitals. Kaiku Health is a part of Elekta.

CONTACT

Ellen Nurmi

Marketing & Communications Manager

ellen.nurmi@kaikuhealth.com

+358 44 551 2744

www.kaikuhealth.com



MULTI-OMICS DATA SOLUTION FOR ONCOLOGY RESEARCH

OUR SOLUTION

MEDISAPIENS Genomics Suite provides pharmaceutical and healthcare organizations with a scalable solution for exploring and performing analytics work on clinical, genomic and other omics data from multiple sources in real time.

COMPETITIVE ADVANTAGE

The MediSapiens Genomics Suite is in use with Bayer AG to support oncology and other drug development. It provides multi-omics data exploration, cohort building and analytics using graphical user interfaces (GUIs) and application program interfaces (APIs) to find new insights in a time- and cost-effective manner. It is optimized to manage large cohorts of data. The largest Nordic private healthcare provider Terveystalo in Finland uses the Genomics Suite to integrate genomics as part of its daily operations, including cancer prevention.

COMPANY

MediSapiens has over a decade of experience providing international clients with innovative biomedical IT solutions. With a mix of bio-informaticians, geneticists and IT professionals, your needs and requirements are fully understood from the beginning.

CONTACT

Hans Garritzen

Sales Director

hans.garritzen@medisapiens.com

+358 50 386 7238

www.medisapiens.com



STATE-OF-THE-ART BREAST CANCER DETECTION

OUR SOLUTION

PLANMED is proud to be one of the world's leading companies fighting breast cancer through sophisticated technology, offering a comprehensive product portfolio in the field of mammography. Our product line consists of solutions suitable for anything from digital and analog breast cancer screening to diagnostic examinations, such as breast tomosynthesis and stereotactic biopsies.

COMPETITIVE ADVANTAGE

Planmed products are well known for their user-friendliness and ergonomics. Outstanding image quality and high performance make the Planmed Clarity™ product family one of the most advanced mammography systems in the market. Today, Planmed Oy's medical imaging solutions can be found in more than 80 countries worldwide. We are continuously expanding and providing our latest technology to clinics and hospitals around the world.

COMPANY

Part of the Finnish Planmeca Group, Planmed Oy was established in 1987 in Helsinki, Finland. We develop, manufacture and offer advanced medical imaging solutions for mammography, orthopedic and maxillofacial imaging. With in-house researchers and designers dedicated to emerging technologies, we are always one step ahead. We are also an industry-leading fore-runner in 3D orthopedic and maxillofacial imaging. In our CBCT line, we have been able to develop the advanced and unique 3D imaging of extremities, head and neck.

CONTACT

Jan Moed
Managing Director
jan.moed@planmed.com
+358 40 766 0196
www.planmed.com



FOR A WORLD WITHOUT FEAR OF CANCER

OUR SOLUTION

At VARIAN, a Siemens Healthineers company, we envision a world without fear of cancer. Our comprehensive product portfolio addresses the complete cancer care continuum – from in-vitro diagnostics and best-in-class imaging to therapy and follow-up care. In the field of radiation therapy, our products include linear accelerators, brachytherapy afterloaders and accessories, as well as software for planning, verifying and delivering advanced radiation, radiosurgery and brachytherapy treatments. We also develop and manufacture proton therapy equipment for highly conformal radiation therapy. Varian software brings care providers, patients, and data together to provide personalized and evidence-based treatment.

COMPETITIVE ADVANTAGE

For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners, helping them treat millions of patients each year. With an Intelligent Cancer Care approach, we harness advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatments and expand access to care.

Products developed in Finland:

- **Eclipse™ Treatment Planning Solution** – fast, precise planning for advanced cancer care
- **Ethos™ Therapy – an Adaptive Intelligence™ solution** combining artificial intelligence and adaptive therapy
- **BrachyVision™ Treatment Planning System** – simplifies the development of complex brachytherapy treatment plans
- **Noona®** – connects cancer clinics with patients online to improve survival and save clinical resources
- **ePeerReview™** and other next-generation Cloud applications

In Finland, almost all cancer hospitals use radiation therapy equipment or software developed by Varian. Our radiotherapy devices account over 80% of all radiotherapy devices sold in Finland.

COMPANY

Varian Finland develops the world's leading radiotherapy treatment planning systems and cancer treatment solutions with a cloud-based mobile application. Most of our employees work in expert positions using their comprehensive skills in programming, applied mathematics, and physics to develop radiotherapy software and cancer treatment solutions. Varian Finland currently employs approximately 300 people from more than 20 nationalities. Since 2021, Varian has been a united company with Siemens Healthineers. Together, we push the boundaries of innovation and accelerate the path from diagnosis to therapy to survivorship.

CONTACT


Kari Toimela

Managing Director

kari.toimela@varian.com

+358 50 310 0241

<http://www.varian.com/finland>



GDPR-FREE REUSE OF CLINICAL DATA / RWD

OUR SOLUTION

Next-generation anonymization technology brings the quality of anonymized health data to the next level. The patented VEIL.AI Anonymization Engine creates extremely high-quality subject-level anonymized and synthetic data that is GDPR-free, providing great new opportunities for various use cases in Life Science and Diagnostics companies, hospitals and all organizations that want to get more out of their data.

COMPETITIVE ADVANTAGE

If you are in need of high-quality health data for RWE (e.g. larger datasets and trans-border data collaborations) or want to reuse your existing clinical data as part of a new Randomized Clinical Trial, you can benefit from our advanced anonymization technology. It can bring new capabilities for a company's own data storage and analytic platforms, as well as hospital data lakes, enabling broader utilization of health data. It enables the development of AI algorithms, providing anonymized or synthetic data. Contact us to learn more about global pharma company references and use cases.

COMPANY

VEIL.AI – the most experienced European health tech company in health data anonymization – has developed and patented AI-based technology that unleashes the power of data. Our customers are Global Life Science and Diagnostics companies, University Hospitals and Biobanks. VEIL.AI is a member of the iCAN Digital Precision Cancer Medicine competence cluster.

CONTACT

Kari Lehtipuu
Chief Commercial Officer
kari.lehtipuu@veil.ai
+358 40 664 6300
www.veil.ai



5. TREATMENT, QUALITY AND CANCER CARE

BUSINESS
FINLAND

We promote equal and immediate access to care for patients and the highest quality care delivery using the latest data-based treatments and solutions.

BCB MEDICAL

CLINIC HELENA

DOCRATES CANCER CENTER

INJEQ

MODULIGHT

MVISION AI

ORTON



BRINGING DATA TO LIFE

OUR SOLUTION

BCB MEDICAL, a digital software and analytics company gathers real-world data (RWD) in a structured format on both medical effectiveness and treatment quality through an integrated proprietary platform from over 100 therapeutic areas including 20 different cancer diseases.

Our mission is to combine, through real time integrations, analyze and present clinical data gathered from various sources in an understandable format, for healthcare professionals and research-based life science industry. These include digital tools for two-way patient communication, and standardised PROM and PREM collection directly from the patient.

COMPETITIVE ADVANTAGE

We have a nationwide solution covering all hospital districts in Finland to gather RWD. Automatically integrated data from various sources, such as EHRs, saves time and resources for HCPs and helps prioritize the patient care to those patients who need it most. The data is used as standard reports for clinics, personalized analytics dashboard for HCPs, national benchmarking, and scientific research projects with also life science involved.

Collected data can be shared for research purposes through FINDATA, with multiple data sources or hospitals ethics approval from one data source.

COMPANY

We can also use federated learning, synthetic data and harmonised data models (OMOP) to assure highest patient privacy. The immense amount of data is also utilised in supporting HCPs in daily treatment decision making through AI and research activities such as digital twins. Our aim is to help develop more personalised care that insures patients are found early, already in primary care, to increase cost effectiveness and patients quality of life.

CONTACT

Lisse-Lotte Hermansson

Chief Scientific Officer

lisse-lotte.hermansson@bcbmedical.com

+358 20 729 9112

<http://www.bcbmedical.com>





BREAST CANCER CARE AND RECONSTRUCTION

OUR SOLUTION

CLINIC HELENA specializes in breast cancer care and reconstructions. “Sensing breast” by Helena Puonti is a unique, microneurovascular technique, which restores sensitivity as the newly reconstructed breast heals. With Clinic Helena’s innovative methods in breast cancer surgery, exact diagnostics and reliable oncologist care, we can save the patient’s breast.

COMPETITIVE ADVANTAGE

Accurate early-stage diagnostics, excellent tailor-made surgery, advanced oncologist care, pioneering rehabilitation and the latest technology and vast experience – all this helps cure patients and help them return to a good quality of life. In 75% of cases, we use breast-conserving surgery to avoid mastectomy. Whenever mastectomy is needed, we reconstruct a “sensing breast” by the aid of microsurgical nerve and blood vessel connection. This technique is unique to Clinic Helena’s oncoplastic microsurgeon Helena Puonti and her team.

COMPANY

Clinic Helena was founded in 1999. We have successfully treated international patients since 2011 and have gained notoriety especially among Russian patients. The percentage of international patients is steadily growing. While our staff speaks seven languages, we are prepared to serve the patients in their own language. Since 2015, we have cooperated with other medical specialists in Finland through Helena Medical Group, offering first-class Finnish healthcare services to foreign patients.

CONTACT

Jenni Eronen

Project Manager

jenni.eronen@clinchelena.com

+358 44 237 8021

www.clinichelena.com





ADVANCED CANCER CARE

OUR SOLUTION

DOCRATES Cancer Center provides services for cancer patients throughout the treatment chain, from diagnosis to treatment and post-treatment follow-up. After diagnosis and imaging, treatment can be planned and initiated without delay.

COMPETITIVE ADVANTAGE

We offer state-of-the-art modern technology, including 3T MRI and positron emission tomography-computed tomography (PET-CT) equipment, robot-aided MRI biopsies and advanced radiotherapy units. Our offering also covers the latest available medical therapies, including the latest nuclear medicines for prostate cancer. As a private European cancer center, we utilize all the latest FDA- and EMA-approved medicines.

COMPANY

Docrates Cancer Center is a private, Finnish-owned, international hospital in Helsinki specializing in individual and comprehensive cancer care. We provide services for cancer patients throughout the treatment chain from diagnosis to treatments and follow-up. After the diagnosis and imaging, treatment can be planned and initiated immediately. Our unique concept attracts patients from all over the world; so far we have treated patients from over 60 countries. Together with our network of leading clinical experts, we provide state-of-the-art cancer therapies in line with our philosophy of individual and patient centered care.

CONTACT

Veronika Kuvshinova

Manager, International Sales and Marketing

veronika.kuvshinova@docrates.com

+358 10 773 2010

www.docrates.com



SAFER LUMBAR PUNCTURES

OUR SOLUTION

INJEQ IQ-Tip® spinal needle is the smartest needle around based on the company's pioneering tissue identification technology. Acute lymphoblastic leukemia (ALL) is the most common cancer type diagnosed in children. Lumbar punctures for sampling cerebrospinal fluid (CSF) and administering cancer medication are critical in treating childhood leukemia. During the treatment, approximately 20 challenging lumbar punctures are performed on the patient. The smart digital technology in the Injeq IQ-Tip® needle system assists the physician in optimal performance of punctures with confidence by alerting the physician immediately with an audio and visual alarm when the needle tip reaches CSF.

COMPETITIVE ADVANTAGE

The Injeq IQ-Tip® needle minimizes treatment delays and additional costs by enabling high first puncture success rate, less traumatic punctures and improved CSF sample quality. When you know where the tip of the needle is, you are able to avoid unnecessary needle movements near the spinal nerves, improving patient safety by reducing the risk of bleeding into the spinal canal. Obtaining a clear CSF sample improves diagnostics and lowers

the probability of cancer cells entering the central nervous system and influencing disease prognosis. Pivotal clinical investigation in three Finnish university hospitals (Helsinki, Tampere and Turku) was completed in autumn 2020.

COMPANY

Injeq was founded by a group of clinical and technology experts who identified a solution for a well-known medical need – to make blind spinal tap punctures safer and more precise. Injeq IQ-Tip System is CE certified by German Notified Body TÜV SÜD and the products are available now in European market area.

CONTACT

Maarit Forstén

Clinical Application Specialist

maarit.forsten@injeq.com

+358 50 543 2912

<http://www.injeq.com>



LASERS FOR MEDICAL APPLICATIONS

OUR SOLUTION

MODULIGHT designs and manufactures lasers for various applications in the field of oncology. We make lasers for therapeutic clinical use as well as for in vivo and in vitro research. We provide lasers for leading cancer centers and pharmaceutical companies globally. The therapeutic applications include uveal melanoma, head and neck cancers, glioblastoma and many others.

COMPETITIVE ADVANTAGE

Photodynamic therapy (PDT) is a treatment that combines a photoactivated drug (photosensitizer) and laser light. Modulight offers lasers that match all photosensitizers commonly used. Even those tumors in hard-to-reach places or difficult to treat with other methods, such as those in the brain, lungs, head and neck, and eyes, can be treated by PDT and lasers.

COMPANY

Modulight, Inc. is an ISO 9001:2015, ISO 14001:2015 and ISO 13485:2016 certified semiconductor laser manufacturer, providing value-added solutions to optical applications for medical, industrial, space and defense & security industries. Our products include various types of lasers from visible to infrared (400–2,000 nm) with output power levels from milliwatts to hundreds of watts.

CONTACT

Seppo Orsila

Chairman & CEO

seppo.orsila@modulight.com

+358 20 743 9000

www.modulight.com



AI-POWERED SOLUTIONS FOR RADIOTHERAPY

OUR SOLUTION

MVISION AI brings AI to medical imaging by helping clinicians automate manual tasks and save time while improving treatment quality. Our first solution is an AI-based SaaS solution that uses artificial intelligence and machine learning to improve the treatment of various types of cancer. This solution automates the target, organ-at-risk segmentation, dose planning and outcome prediction for radiotherapy. Our deep learning-based segmentation tool labels organs in computed tomography (CT) and magnetic resonance imaging (MRI) scans in seconds instead of the hours required for manual drawing. It reduces treatment planning time by up to 40%. Artificial intelligence helps create consistent contours with less variation, providing a reliable starting point for clinicians.

COMPETITIVE ADVANTAGE

MVision helps hospitals streamline radiotherapy treatment planning with cloud-based software for automatic organs-at-risk (OAR) segmentation. Using deep learning, the software has been developed according to global consensus guidelines, such as ESTRO ACROP 2018, to produce the highest-quality standardized contours every time.

MVision is also developing AI-based algorithms for dose and outcome predictions to reduce radiation to healthy tissues and improve patient outcomes. Since 2018, Mvision has been installed in multiple hospitals in Europe, including Docrates Cancer Center and Turku University Hospital in Finland and Strahlentherapie Singen in Germany.

COMPANY

Founded in 2017, Mvision AI is based in Helsinki. The company develops advanced automatic segmentation, registration, resampling, CT synthesis, reconstruction and treatment planning artificial intelligence as the future of radiotherapy. We believe the development of medical software can be fast paced without compromising quality and safety.

CONTACT

Mahmudul Hasan
CEO & Founder
mhasan@mvision.ai
+358 40 548 9229
www.mvision.ai



UNIVERSITY HOSPITAL COMPREHENSIVE CANCER CARE

OUR SOLUTION

ORTON provides cutting-edge cancer care at Finland's biggest cancer center – HUS Helsinki University Hospital Comprehensive Cancer Center.

COMPETITIVE ADVANTAGE

Orton provides HUS Helsinki University Hospital's healthcare services for private international patients. Orton's patients benefit from the university hospital's oncology expertise, latest surgical practices and treatments and modern facilities while receiving personalized customer service. Focusing on demanding and specialized healthcare services, Orton's services include oncology and surgery for different types of cancer.

COMPANY

Orton is the most extensive private provider of specialized health care in Finland.

In addition to joint replacements and spinal surgery the hospital offers oncology treatments and cancer surgery as well as a wide variety of other specialized health care services in cooperation with HUS Helsinki University Hospital.

CONTACT

Orton Cancer treatment inquiries
operation@orton.fi
+358 4748 2704
www.orton.fi

6. LIFE MANAGEMENT

BUSINESS
FINLAND


We empower cancer patients through support and engagement at all stages to guarantee the highest quality of life for patients living with cancer.

AUNTIE SOLUTIONS

KINDFULL

LYMPHATOUCH

POPIT





EASY ACCESS TO MENTAL WELL-BEING SERVICES

OUR SOLUTION

AUNTIE supports people in different stages of life – whether it is divorce, stress, lost motivation, overachieving or chronic pain you are struggling with, Auntie’s concept can support you. Also, if you receive a severe diagnosis, you may want to talk to someone – after all, life is turning upside down at that point. Auntie’s service includes five video sessions with an Auntie professional psychologist or other health specialist with tests, assignments and tasks between the sessions. Our unique concept will make you feel better.

COMPETITIVE ADVANTAGE

On average, stress levels go down more than 25% and happiness increases just about as much. You cannot get medicine or sick leave days from Auntie, but you can feel better after talking to someone and maybe getting a fresh view of your situation. Examples of reference cases include, among others, the City of Helsinki, the City of Turku and larger organizations.

COMPANY

Auntie was founded in 2015 to remove the stigma from mental health issues and to give preventive and early-stage support for people needing it – and we all need it at some point in our lives. Currently, we operate globally and serve our customers in 12 different languages. We have more than 60 professionals ready to help with Auntie’s concept.

CONTACT


Mervi Lamminen

CEO

mervi.lamminen@auntie.fi

+358 50 380 5602

<http://www.auntiesolutions.com>



HARNESSING THE POWER OF COMMUNITIES

OUR SOLUTION

KINDFULL is a patient support solution for home and healthcare providers and pharmaceuticals. The app allows recently discharged in-home patients to receive community support, transforming their in-home experience. This app provides emotional support, trusted information and community for cancer patients and their friends and family. Support for friends and family takes the stigma of sickness away and helps them to stay connected with the patient. Shared and trusted information reduces unnecessary fears and strengthens treatment adherence and outcomes. It activates the therapeutic benefits of community support and thus drives improved health outcomes.

COMPETITIVE ADVANTAGE

Kindfull provides an app-based patient support network that opens pathways to community connections and the therapeutic benefits of community support – including family, friends, non-profits and for-hire resources. Benefits of this support include companionship, guidance, assistance and community. Over time, it activates the therapeutic benefits of community support and yield. This includes improved patient support at home. In the long run, the app will increase patient satisfaction,

enable better patient outcomes and enhance provider reputation and key performance indicators.

COMPANY

The Kindfull startup was established in 2017. It was formerly known as “Huoleti,” which means “worry-free” in Finnish. Our headquarters are located in the beautiful city of Tampere, Finland. The concept is the result of an innovation competition organized by Helsinki University Hospital to support cancer patients during their treatments. The solution has been further developed with patients and patient advocacy groups in dozens of projects to provide support in various life-changing situations. Specialists in IT security, healthcare, business development and technology are continuously involved in the work.

CONTACT

Carita Savin

Co-founder & CEO

carita.savin@kindfull.io

+358 40 562 1700

www.kindfull.io





THERAPEUTIC EXCELLENCE FOR FASTER RECOVERY

OUR SOLUTION

LYMPHATOUCH® is a unique and easy-to-use medical device for healthcare professionals, designed to relieve swelling and pain in primary and secondary lymphedema, after traumas and injuries, as well as pre- and postoperatively. It combines negative pressure and mechanical vibration to ensure the best therapy outcome.

COMPETITIVE ADVANTAGE

LymphaTouch® treatment activates efficiently the lymphatic flow and the transportation of fluids in the subcutaneous tissue to increase oxygen and nutrient flow around the treated area. This improves fluid reduction and relieves both swelling and discomfort. Our technology is presented globally in large institutions such as Vanderbilt University Medical Center and Johns Hopkins Hospital. LymphaTouch® is also widely used by healthcare professionals in private clinics.

COMPANY

Founded in 2005, LymphaTouch Inc. has been offering negative pressure solutions since 2009. We are a fast-growing, ISO 13485:2016 -certified medical device company. Our headquarters are in Helsinki, Finland, from where provide a solid solution.

CONTACT

Tiina Smeds

Sales & Marketing Manager

tiina.smeds@lymphatouch.com

+358 40 564 0824

www.lymphatouch.com



DIGITIZING MEDICATION

OUR SOLUTION

POPIT takes medication adherence to a new level with a unique digital solution that automatically tracks how patients take medication. Popit's solution consists of a unique device, an app and cloud-based assistance. The patented device tracks medication consumption automatically without requiring changes to medication packaging, while the cloud platform sends customized engagement messages to support the patient's treatment journey. For oncology patients, Popit not only provides adherence support but also an easy way to stay in touch with healthcare professionals and the patient support program. Based on adherence, patients can be proactively contacted by healthcare professionals. These features improve treatment outcomes, patient support and quality of life. Additionally, Popit's solution gathers real-time data on how medications are taken. This data can be used for further research on understanding different patient segments. Popit's adherence and engagement platform can easily be upgraded into a full patient support program (PSP), providing the patient with treatment reference materials and contacts through the app.

COMPETITIVE ADVANTAGE

Together with leading pharmaceutical companies, Popit improves medication adherence by over 25% and produces real-world data.

References already include Pfizer (rheumatoid arthritis, ulcerative colitis), Novartis (neurology), Almirall (psoriasis) and Servier (cardiology, type 2 diabetes). Popit's experience in various therapeutic areas is invaluable in tackling even more difficult indications. We provide the tools to improve adherence and engagement, as well as the means to communicate directly with the patient. The solution is clinically validated to reduce missed pills by over 80% using innovative technology to help engage patients.

COMPANY

Popit is an innovative startup from Espoo, Finland. Established in 2015, the company has already obtained some of the world's largest pharmaceutical companies as customers. Popit is dedicated to making medication connected so that pharmaceutical products can be placed at the center of a service ecosystem powered by medication consumption data.

CONTACT

Timo Heikkilä
COO, Co-founder
timo@popit.io
+358 50 487 3728
www.popit.io



CONTACT INFORMATION

**BUSINESS
FINLAND**

Business Finland

Terhi Rasmussen, Global Opportunity Leader / Health & Wellbeing

+45 20 54 98 94

terhi.rasmussen@businessfinland.fi

BUSINESSFINLAND.COM

Notice: The information contained in this publication is collected from various sources and provided for your information only. Business Finland does not assume any liability for the accuracy and completeness of the information.